Jin-Ji Yang, MD is an oncologist at Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, at the Guangdong Academy of Medical Sciences at the Southern Medical University.

Dr Yang, MD, on Osimertinib Plus Savolitinib in MET-Aberrant, EGFR-Mutant Advanced NSCLC

“The overall response rate [with osimertinib plus savolitinib] was [over] 90%—a remarkable increase [compared with osimertinib alone].”

Jin-Ji Yang, MD, Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, discusses findings from the phase 2 FLOWERS trial (NCT05163249) evaluating osimertinib (Tagrisso) in combination with savolitinib as a first-line treatment for patients with de novo 

-mutant advanced non–small cell lung cancer (NSCLC).

This open-label, randomized study enrolled treatment-naive patients with 

 alterations to receive either osimertinib plus savolitinib (n = 21) or osimertinib monotherapy (n = 23). Findings demonstrated a statistically significant improvement in objective response rate (ORR) with the combination therapy compared with osimertinib alone, Yang begins. At the May 28, 2024, data cutoff and a median follow-up of 8.2 months, the ORR was 90.5% (95% CI, 69.6%-98.8%) in the combination arm vs 60.9% (95% CI, 38.5%-80.3%) in the monotherapy arm. The disease control rates were also 95.2% (95% CI, 76.2%-99.9%) vs 87.0% (95% CI, 66.4%-97.2%), respectively.

Additionally, although progression-free survival (PFS) data were immature, they suggested a potential clinical benefit with the combination regimen. The median PFS was 13.4 months (95% CI, 10.2-not evaluable [NE]) in the combination arm vs 9.5 months (95% CI, 7.4-NE) with osimertinib alone (HR, 0.80; 95% CI, 0.19-1.81).

Osimertinib plus savolitinib demonstrated a manageable safety profile consistent with prior studies. Any-grade treatment-emergent adverse effects (TEAEs) occurred in all patients in both arms. The rates of grade 3 or higher TEAES was 71.4% for the combination vs26.1% for osimertinib alone. TEAEs led to dose reduction in 23.8% of patients in the combination arm. No TEAEs led to death in any arm.

Videos

Jin-Ji Yang, MD, discusses osimertinib plus savolitinib as a first-line treatment in patients with de novo MET-aberrant, EGFR-mutant advanced NSCLC.

Jin-Ji Yang, MD

Articles

Dr Yang on Osimertinib Plus Savolitinib in MET-Aberrant, EGFR-Mutant Advanced NSCLC